Photoredox route to medically-important heterocycles


Researchers in the US have developed a new photocatalysed coupling reaction that could provide a pathway to a huge number of biologically active compounds.

The coupling mechanism uses chloroheteroarenes in the direct α-arylation of amines

Heterocycles and heteroaromatic compounds are of great interest to medicinal chemists, due to their widespread use in pharmaceuticals. They are able to increase the aqueous solubility and decrease the lipophilicity of drugs, as well as improving their potency and biocompatibility.

It is therefore important to explore reactions that can couple heterocyclic moieties to other molecular fragments, in order to synthesise a variety of drugs. One such reaction is the α-heteroarylation of tertiary amines, which is an unusual construction that is difficult to achieve with typical reagents.

Christopher Prier and David MacMillan, at Princeton University, New Jersey, have found a straightforward and elegant way of doing this, using an iridium photocatalyst. ‘What is really exciting about these photocatalysts is that you can use visible light to excite them,’ says Prier. This is useful because the catalyst can be selectively excited without affecting the activity of any of the other reagents.

The most likely mechanism for this reaction is as follows. The Ir3+ catalyst is converted to its photoexcited state under visible light, and goes on to oxidise the tertiary amine to its radical cation by single electron transfer (SET). Elimination of H+ provides an α-amino radical, which then attacks the electron deficient heterocycle, coupling the two moieties together. Ir2+ then gives up an electron to the newly made complex, oxidising itself back to Ir3+ and enabling Cl to leave, rendering the entire process redox neutral. No stoichiometric oxidising or reducing agents are required.

The reaction is thought to proceed via a homolytic aromatic substitution reaction

This reaction is extraordinarily versatile, and has been demonstrated to work on a large range of five- and six-membered heterocycles with different functional groups, and both cyclic and acyclic amines. Prier would now like to extend its use to other substrates, such as secondary amines and more electron-rich heterocycles.

Matthew Gaunt, who works on controlled synthesis at the University of Cambridge, in the UK, points out how this work has overcome potential challenges. ‘What is particularly impressive is the ability to use the sort of electron deficient aromatic heterocycles that are ubiquitous in drug-like molecules.’

Total synthesis specialist Steven Weinreb, of Pennsylvania State University, US, is also enthusiastic about the work, ‘Alpha carbo-functionalisation of amines is a longstanding problem in organic synthesis,’ he says. ‘This new methodology is a major advance in this area, and is both clever and practical.’

References

This paper is free to access until 24 September 2014. Download it here:

C Prier and D MacMillan, Chem. Sci., 2014, DOI: 10.1039/c4sc02155j


Related Content

For clean carbon dioxide conversion just add water

21 December 2011 News Archive

news image

A photocatalytic system has been created that can turn carbon dioxide into basic chemical building blocks

Catalyst clears up corrosion

7 December 2011 News Archive

news image

Photocatalyst ink provides a cheap and easy way to clean metals in industry

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company